Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cidara Therapeutics, Inc. (CDTX)
|
Add to portfolio |
|
|
|
| Price: |
$2.16
| | Metrics |
| OS: |
90.3
|
M
| |
-73
|
% ROE
|
| Market cap: |
$195
|
M
| |
-43
|
% ROIC
|
|
Net cash:
|
$50.4
|
M
| |
$0.56
|
per share
|
|
EV:
|
$145
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($8.1)
|
M
| |
|
|
|
EBIT
|
($8.2)
|
M
| |
|
|
| EPS |
($0.17)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 64.3 | 49.6 | 12.1 | 20.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 29.7% | 310.8% | -42.3% | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 64.3 | 49.6 | 12.1 | 20.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | | | | |
| Research and development | 75.5 | 73.1 | 68.0 | 46.4 | 49.1 | 42.8 | 35.7 | 23.5 |
| General and administrative | 18.5 | 18.7 | 15.9 | 16.2 | 14.1 | 12.9 | 12.7 | 8.8 |
| EBIT | -29.7 | -42.3 | -71.8 | -41.7 | -63.3 | -55.7 | -48.4 | -32.3 |
| EBIT margin | -46.2% | -85.2% | -595.4% | -199.5% | | | | |
| Pre-tax income | -29.5 | -42.5 | -72.1 | -41.1 | -59.0 | -55.7 | -48.2 | -32.2 |
| Income taxes | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -29.8 | -42.5 | -74.9 | -41.1 | -69.3 | -55.7 | -48.2 | -32.2 |
| Net margin | -46.4% | -85.7% | -620.5% | -196.5% | | | | |
| |
| Diluted EPS | ($0.43) | ($0.81) | ($1.80) | ($1.37) | ($2.68) | ($3.18) | ($3.32) | ($3.25) |
| Shares outstanding (diluted) | 69.9 | 52.5 | 41.6 | 29.9 | 25.9 | 17.5 | 14.5 | 9.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|